Literature DB >> 28316001

Associations of polymorphisms in the candidate genes for Alzheimer's disease BIN1, CLU, CR1 and PICALM with gestational diabetes and impaired glucose tolerance.

Gabriela Vacínová1,2, D Vejražková3, P Lukášová3, O Lischková3, K Dvořáková3, R Rusina4,5, I Holmerová6, H Vaňková6,7, J Včelák3, B Bendlová3, M Vaňková3.   

Abstract

Alzheimer's disease (AD) is the most common type of dementia, with a prevalence that is rising every year. AD is associated with type 2 diabetes mellitus (T2DM) and insulin resistance, and is therefore sometimes called "type 3 diabetes mellitus". The aim of this study was to examine whether the variants of some candidate genes involved in the development of AD, namely BIN1 (rs744373), CLU (rs11136000), CR1 (rs3818361), and PICALM (rs3851179), are related to several disorders of glucose metabolism-gestational diabetes (GDM), T2DM and impaired glucose tolerance (IGT). Our study included 550 women with former GDM and 717 control women, 392 patients with T2DM and 180 non-diabetic controls, and 117 patients with IGT and 630 controls with normal glucose tolerance. Genotyping analysis was performed using specially-designed TaqMan assays. No significant associations of the genetic variants rs744373 in BIN1, rs11136000 in CLU, or rs3818361 in CR1 were found with GDM, T2DM or IGT, but rs3851179 in PICALM was associated with an increased risk of GDM. The frequency of the AD risk-associated C allele was significantly higher in the GDM group compared to controls: OR 1.21; 95% CI (1.03-1.44). This finding was not apparent in T2DM and IGT; conversely, the C allele of the PICALM SNP was protective for IGT: OR 0.67; 95% CI (0.51-0.89). This study demonstrates an association between PICALM rs3851179 and GDM as well as IGT. However, elucidation of the possible role of this gene in the pathogenesis of GDM requires further independent studies.

Entities:  

Keywords:  Alzheimer’s disease; Gestational diabetes mellitus; Glucose metabolism; Impaired glucose tolerance; Polymorphisms; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2017        PMID: 28316001     DOI: 10.1007/s11033-017-4100-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  19 in total

1.  Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.

Authors:  Enrique J Rivera; Alison Goldin; Noah Fulmer; Rose Tavares; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2005-12       Impact factor: 4.472

2.  MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease.

Authors:  G Bartzokis; T A Tishler
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2000-06       Impact factor: 1.770

3.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

Authors:  Eric Steen; Benjamin M Terry; Enrique J Rivera; Jennifer L Cannon; Thomas R Neely; Rose Tavares; X Julia Xu; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2005-02       Impact factor: 4.472

4.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Authors:  Denise Harold; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Marian L Hamshere; Jaspreet Singh Pahwa; Valentina Moskvina; Kimberley Dowzell; Amy Williams; Nicola Jones; Charlene Thomas; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; John Hardy; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Hendrik van den Bussche; Isabella Heuser; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Kristel Sleegers; Karolien Bettens; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panagiotis Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Magda Tsolaki; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; Peter A Holmans; Michael O'Donovan; Michael J Owen; Julie Williams
Journal:  Nat Genet       Date:  2009-09-06       Impact factor: 38.330

5.  Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic iron homeostasis dysregulation.

Authors:  Ângela C Crespo; Bruno Silva; Liliana Marques; Erica Marcelino; Carolina Maruta; Sónia Costa; Angela Timóteo; Arminda Vilares; Frederico Simões Couto; Paula Faustino; Ana Paula Correia; Ana Verdelho; Graça Porto; Manuela Guerreiro; Ana Herrero; Cristina Costa; Alexandre de Mendonça; Luciana Costa; Madalena Martins
Journal:  Neurobiol Aging       Date:  2013-10-17       Impact factor: 4.673

Review 6.  Genome-wide association studies in Alzheimer disease.

Authors:  Stephen C Waring; Roger N Rosenberg
Journal:  Arch Neurol       Date:  2008-03

Review 7.  Reassessing the amyloid cascade hypothesis of Alzheimer's disease.

Authors:  Sanjay W Pimplikar
Journal:  Int J Biochem Cell Biol       Date:  2008-12-30       Impact factor: 5.085

Review 8.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders.

Authors:  Carlo Ballatore; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2007-09       Impact factor: 34.870

9.  Modulation of PICALM Levels Perturbs Cellular Cholesterol Homeostasis.

Authors:  Jacob L Mercer; Joseph P Argus; Donna M Crabtree; Melissa M Keenan; Moses Q Wilks; Jen-Tsan Ashley Chi; Steven J Bensinger; Catherine P Lavau; Daniel S Wechsler
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

10.  Genome-wide association study of Alzheimer's disease.

Authors:  M I Kamboh; F Y Demirci; X Wang; R L Minster; M M Carrasquillo; V S Pankratz; S G Younkin; A J Saykin; G Jun; C Baldwin; M W Logue; J Buros; L Farrer; M A Pericak-Vance; J L Haines; R A Sweet; M Ganguli; E Feingold; S T Dekosky; O L Lopez; M M Barmada
Journal:  Transl Psychiatry       Date:  2012-05-15       Impact factor: 6.222

View more
  3 in total

1.  High glucose-mediated PICALM and mTORC1 modulate processing of amyloid precursor protein via endosomal abnormalities.

Authors:  Chang Woo Chae; Hyun Jik Lee; Gee Euhn Choi; Young Hyun Jung; Jun Sung Kim; Jae Ryong Lim; Seo Yihl Kim; In Koo Hwang; Je Kyung Seong; Ho Jae Han
Journal:  Br J Pharmacol       Date:  2020-07-14       Impact factor: 8.739

2.  Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gestational diabetes mellitus.

Authors:  Varun Alur; Varshita Raju; Basavaraj Vastrad; Anandkumar Tengli; Chanabasayya Vastrad; Shivakumar Kotturshetti
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

3.  Evaluating the Causal Effects of Gestational Diabetes Mellitus, Heart Disease, and High Body Mass Index on Maternal Alzheimer's Disease and Dementia: Multivariable Mendelian Randomization.

Authors:  Jie Sheng; Jundong Liu; Kei Hang Katie Chan
Journal:  Front Genet       Date:  2022-06-21       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.